MedTrace Logo

A Study of Omega-3 as a Treatment for Major Depression

NCT00238758 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2006-09-13

No results posted yet for this study

Summary

The purpose of this study is to determine whether omega-3 polyunsaturated fatty acids are effective as a monotherapy for depression.

Conditions

Interventions

DRUG

Omega-3 Polyunsaturated Fatty Acids

Sponsors & Collaborators

  • Your Health Inc.

    collaborator OTHER

  • Sphere Healthcare

    collaborator INDUSTRY

  • Ocean Nutrition

    collaborator INDUSTRY

  • The University of New South Wales

    lead OTHER

Principal Investigators

  • Anne Marie Rees, BSc MBBS · Senior Research Fellow and Consultant Psychiatrist, School of Psychiatry, UNSW & Black Dog Institute

  • Gordon B Parker, Dsc MD PhD · Professor, School of Psychiatry UNSW and Executive Director, Black Dog Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00238758 on ClinicalTrials.gov